In this study, we confirmed the upregulation of the downstream target genes, GRP78 and Bcl-2, by miR-181a downregulation of IhOM-MSCs, when compared with OM-MSCs that were not pretreated. The gene discussed is BCL2; the disease is ocular melanoma.